Complications of Myeloma Therapy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The advent of new therapies for multiple myeloma brings new hope for patients but also new side effects. Emerging information about the risks of supportive care therapies, including long-term, high-intensity bisphosphonate use and erythropoiesis-stimulating agents, is examined. As the number of drugs in the myeloma armamentarium grows, so does the list of possible side effects and interactions. With current progress, not only are there more complications to consider but patients are also living longer and the risk for delayed complications is becoming more relevant. The author provides perspective about the risks for the most active and commonly used single-agent and combination myeloma therapies.

Original languageEnglish (US)
Pages (from-to)1247-1273
Number of pages27
JournalHematology/Oncology Clinics of North America
Volume21
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Hematinics
Diphosphonates
Multiple Myeloma
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Complications of Myeloma Therapy. / Dispenzieri, Angela.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 6, 12.2007, p. 1247-1273.

Research output: Contribution to journalArticle

@article{d203da9f0eb6435494f3af6a2ca91bd4,
title = "Complications of Myeloma Therapy",
abstract = "The advent of new therapies for multiple myeloma brings new hope for patients but also new side effects. Emerging information about the risks of supportive care therapies, including long-term, high-intensity bisphosphonate use and erythropoiesis-stimulating agents, is examined. As the number of drugs in the myeloma armamentarium grows, so does the list of possible side effects and interactions. With current progress, not only are there more complications to consider but patients are also living longer and the risk for delayed complications is becoming more relevant. The author provides perspective about the risks for the most active and commonly used single-agent and combination myeloma therapies.",
author = "Angela Dispenzieri",
year = "2007",
month = "12",
doi = "10.1016/j.hoc.2007.08.002",
language = "English (US)",
volume = "21",
pages = "1247--1273",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Complications of Myeloma Therapy

AU - Dispenzieri, Angela

PY - 2007/12

Y1 - 2007/12

N2 - The advent of new therapies for multiple myeloma brings new hope for patients but also new side effects. Emerging information about the risks of supportive care therapies, including long-term, high-intensity bisphosphonate use and erythropoiesis-stimulating agents, is examined. As the number of drugs in the myeloma armamentarium grows, so does the list of possible side effects and interactions. With current progress, not only are there more complications to consider but patients are also living longer and the risk for delayed complications is becoming more relevant. The author provides perspective about the risks for the most active and commonly used single-agent and combination myeloma therapies.

AB - The advent of new therapies for multiple myeloma brings new hope for patients but also new side effects. Emerging information about the risks of supportive care therapies, including long-term, high-intensity bisphosphonate use and erythropoiesis-stimulating agents, is examined. As the number of drugs in the myeloma armamentarium grows, so does the list of possible side effects and interactions. With current progress, not only are there more complications to consider but patients are also living longer and the risk for delayed complications is becoming more relevant. The author provides perspective about the risks for the most active and commonly used single-agent and combination myeloma therapies.

UR - http://www.scopus.com/inward/record.url?scp=35748954667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748954667&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2007.08.002

DO - 10.1016/j.hoc.2007.08.002

M3 - Article

C2 - 17996597

AN - SCOPUS:35748954667

VL - 21

SP - 1247

EP - 1273

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -